A Phase 2 Randomized Trial of Asleep versus Awake Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease.


Journal

Stereotactic and functional neurosurgery
ISSN: 1423-0372
Titre abrégé: Stereotact Funct Neurosurg
Pays: Switzerland
ID NLM: 8902881

Informations de publication

Date de publication:
2021
Historique:
received: 19 05 2020
accepted: 07 09 2020
pubmed: 1 12 2020
medline: 25 2 2023
entrez: 30 11 2020
Statut: ppublish

Résumé

Asleep deep brain stimulation (DBS) for Parkinson's disease (PD) is being performed more frequently; however, motor outcomes and safety of asleep DBS have never been assessed in a prospective randomized trial. We conducted a prospective, randomized, noncomparative trial to assess the motor outcomes of asleep DBS. Leads were implanted in the subthalamic nucleus (STN) according to probabilistic stereotactic coordinates with a surgical robot under O-arm© imaging guidance under either general anesthesia without microelectrode recordings (MER) (20 patients, asleep group) or local anesthesia with MER and clinical testing (9 patients, awake group). The mean motor improvement rates on the Unified Parkinson's Disease Rating Scale Part III (UPDRS-3) between OFF and ON stimulation without medication were 52.3% (95% CI: 45.4-59.2%) in the asleep group and 47.0% (95% CI: 23.8-70.2%) in the awake group, 6 months after surgery. Except for a subcutaneous hematoma, we did not observe any complications related to the surgery. Three patients (33%) in the awake group and 8 in the asleep group (40%) had at least one side effect potentially linked with neurostimulation. Owing to its randomized design, our study supports the hypothesis that motor outcomes after asleep STN-DBS in PD may be noninferior to the standard awake procedure.

Identifiants

pubmed: 33254172
pii: 000511424
doi: 10.1159/000511424
doi:

Banques de données

ClinicalTrials.gov
['NCT01817088']

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

230-240

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Julien Engelhardt (J)

CHU de Bordeaux, Service de Neurochirurgie B, Bordeaux, France, julien.engelhardt@gmail.com.
Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France, julien.engelhardt@gmail.com.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France, julien.engelhardt@gmail.com.

François Caire (F)

Université de Limoges, CNRS, XLIM, UMR7252, Limoges, France.
CHU de Limoges, Service de Neurochirurgie, Limoges, France.

Nathalie Damon-Perrière (N)

Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Service d'explorations Fonctionnelles du Système Nerveux, Bordeaux, France.

Dominique Guehl (D)

Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Service d'explorations Fonctionnelles du Système Nerveux, Bordeaux, France.

Olivier Branchard (O)

CHU de Bordeaux, Service de Neurochirurgie B, Bordeaux, France.

Nicolas Auzou (N)

CHU de Bordeaux, Service de Neurologie, Bordeaux, France.
Laboratoire de Psychologie, Université de Bordeaux, Bordeaux, France.

François Tison (F)

Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Service de Neurologie, Bordeaux, France.

Wassilios G Meissner (WG)

Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Service de Neurologie, Bordeaux, France.

Elsa Krim (E)

CH de Pau, Service de Neurologie, Pau, France.

Stéphanie Bannier (S)

CH de Bayonne, Service de Neurologie, Bayonne, France.

Antoine Bénard (A)

CHU Bordeaux, Pôle de Santé Publique, Clinical Epidemiology Unit (USMR), Bordeaux, France.

Rémi Sitta (R)

CHU Bordeaux, Pôle de Santé Publique, Clinical Epidemiology Unit (USMR), Bordeaux, France.

Denys Fontaine (D)

CHU de Nice, Service de Neurochirurgie, Nice, France.
Université Côte d'Azur, Nice, France.

Xavier Hoarau (X)

Polyclinique de Navarre, Service de Neurochirurgie, Pau, France.

Pierre Burbaud (P)

Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Service d'explorations Fonctionnelles du Système Nerveux, Bordeaux, France.

Emmanuel Cuny (E)

CHU de Bordeaux, Service de Neurochirurgie B, Bordeaux, France.
Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH